Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.53 |
| ▸ | CHUK | O15111 | 8/20 | 0.53 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | NEK1 | Q96PY6 | 5/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | CIT | O14578 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009578 | 0.96 | PIK3C3 (0.55) | IKBKBCHUKPIK3C3JAK1PRKCI | |
| SCHEMBL30009803 | 0.86 | IKBKB (0.55) | IKBKBCHUKJAK1PRKCINEK1 | |
| SCHEMBL30010083 | 0.85 | PIK3C3 (0.54) | IKBKBCHUKPIK3C3JAK1PRKCI | |
| SCHEMBL30009338 | 0.84 | JAK1 (0.54) | IKBKBCHUKJAK1PRKCINEK1 | |
| SCHEMBL30009353 | 0.82 | JAK1 (0.61) | IKBKBCHUKJAK1PRKCINEK1 | |
| SCHEMBL30009401 | 0.81 | PIK3C3 (0.57) | IKBKBCHUKPIK3C3JAK1PRKCI | |
| SCHEMBL30009836 | 0.80 | PIK3C3 (0.59) | IKBKBCHUKPIK3C3JAK1PRKCI | |
| SCHEMBL30009209 | 0.80 | JAK1 (0.59) | IKBKBCHUKPIK3C3JAK1CCNK | |
| SCHEMBL30008725 | 0.80 | IKBKB (0.69) | IKBKBCHUKPIK3C3JAK1NEK1 | |
| SCHEMBL20917882 | 0.79 | JAK1 (0.78) | JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | IKBKB 294/4885CHUK 53/4885PIK3C3 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.